Aytu BioPharma, Inc. (AYTU) compared with its closest peers (NNVC, OPTH, BTAI, ATOS, CLRB). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| NanoViricides, Inc. (NNVC) | $28.68M | -2.1 |
| Optimi Health Corp. (OPTH) | $27.43M | — |
| BioXcel Therapeutics, Inc. (BTAI) | $25.35M | -0.3 |
| Atossa Therapeutics, Inc. (ATOS) | $25.30M | -0.1 |
| Cellectar Biosciences, Inc. (CLRB) | $24.39M | -0.3 |
| TherapeuticsMD, Inc. (TXMD) | $23.79M | 47.9 |
| ABVC BioPharma, Inc. (ABVC) | $23.38M | -5.4 |
| Marker Therapeutics, Inc. (MRKR) | $23.09M | -1.8 |
| Allarity Therapeutics, Inc. (ALLR) | $22.28M | -1.4 |
| Biofrontera Inc. (BFRI) | $21.91M | -0.7 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
AYTU overview · AYTU earnings · AYTU financials · AYTU KPIs · AYTU investor relations · AYTU ownership · AYTU filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.